Di Silveiro F, La Pera G, De Matties A, De Vita R
Department of Urology, University of Rome La Sapienza, Italy.
Arch Esp Urol. 1991 Apr;44(3):319-23.
During the past 10 years we have studied 216 patients with renal cell carcinoma (RCC). After nephrectomy the patients were divided into two groups: one group received adjuvant acetate medroxyprogesterone therapy and the other formed our control group. The mean follow-up was 4.9 years. Survival was studied through univariate and multivariate analysis, according to Cox's multiple regression. To evaluate survival the following variables were taken into consideration: stage, grade, ploidy, sex, age, MAP therapy, Er, AR, PR receptors. The survival curves according to Kaplan and Meier were statistically significant for stage, grade, MAP therapy and DNA cellular content. The other variables were not statistically significant prognostic factors. Multivariate analysis demonstrated that only stage and MAP therapy are capable of influencing survival. A low stage has a better survival rate and in equivalent stages those who have received MAP live longer.
在过去10年里，我们研究了216例肾细胞癌（RCC）患者。肾切除术后，患者被分为两组：一组接受醋酸甲羟孕酮辅助治疗，另一组作为我们的对照组。平均随访时间为4.9年。根据Cox多元回归进行单因素和多因素分析以研究生存率。为评估生存率，考虑了以下变量：分期、分级、倍性、性别、年龄、MAP治疗、雌激素受体（Er）、雄激素受体（AR）、孕激素受体（PR）。根据Kaplan-Meier法绘制的生存曲线显示，分期、分级、MAP治疗和DNA细胞含量具有统计学意义。其他变量不是具有统计学意义的预后因素。多因素分析表明，只有分期和MAP治疗能够影响生存率。分期低的患者生存率更高，在相同分期的患者中，接受MAP治疗的患者存活时间更长。
